Shots: The companies collaborated to form JV to develop, manufacture, and commercialize biosimilars for a global market The collaboration will utilize Cipla and Kemwell’s strengths for product development, clinical development, […]readmore
Tags : Joint Venture
Shots: The two companies will co-develop and conduct clinical trials for senaparib across multiple cancer indications in China. Junshi to invest $43.4M in cash, representing 50% of the JV while […]readmore
Shots: The companies partnered to form JV focusing on the marketing, market access, and medical affairs activities for the IV iron portfolio. Vifor Pharma will own 55% while the Fresenius […]readmore
Shots: Joint Venture will combine StemoniX’s human microOrgan platform with Atomwise’s AI technology to allow the rapid discovery and development of novel therapies, initially targeting Rett syndrome Atomwise will utilize […]readmore
Shots: JWP to acquire all stock of Chugai in C&C by 31 Dec 2019. C&C will be a wholly-owned subsidiary of JWP and will continue its R&D with independent management. […]readmore
Shots: Ferring launches a new company FerGene focusing the global development and commercialization of Nadofaragene firadenovec in the US for the patients with Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder […]readmore
Shots: Evotec to apply its drug discovery & development capabilities plus will utilize Vifor Pharma’s platform for creating pipeline of nephrology program and with the completion of clinical trials evaluating […]readmore
Shots: GSK to receive 68% equity stake and Pfizer to receive 32% equity stake in consumer health business joint venture The focus of the agreement is to establish a joint […]readmore
Shots: Novartis to receive $13B (£9.2B) as total deal value from GSK. GSK to acquire 36.5% stake (63.5% already acquired in 2014) in Consumer Healthcare Joint Venture, formed in 2014 […]readmore